ArticleFrontiers in immunology2022
CXCL13 is elevated in inflammatory bowel disease in mice and humans and is implicated in disease pathogenesis.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- A Modelling Approach to Resolve Gene Temporal Dynamics in Intestinal Inflammation.Methods in molecular biology (Clifton, N.J.) · 2027Article
- IRF4 p.T95R combined immunodeficiency: Clinical features and transplant outcomes.Journal of human immunity · 2026Article
- A Versatile Anti-CXCR5 Monoclonal Antibody (CxCurrent issues in molecular biology · 2026Article
- A Probiotic Mixture Neuralli™-CORE Attenuates DSS-Induced Colitis by Enhancing Gut Microbiota Resilience in Mice.International journal of molecular sciences · 2026Article
- Adiponectin deficiency prevents chronic colitis-associated colonic fibrosis via inhibiting CXCL13 production.Journal of advanced research · 2025Article
- The regulatory functions of G protein-coupled receptors signaling pathways in B cell differentiation and development contributing to autoimmune diseases.Cell & bioscience · 2025Review
- Spatial transcriptomics delineates potential differences in intestinal phenotypes of cardiac and classical necrotizing enterocolitis.iScience · 2025Article
- Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19.Blood · 2025Article
- Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease.Clinical and experimental immunology · 2025Article
- The utility of CXCL13 and circulating CXCR5Frontiers in immunology · 2025Article
- CXCL13: a common target for immune-mediated inflammatory diseases.Clinical and experimental medicine · 2024Review
- Serum CXCL13 as a Novel Biomarker in Oral Squamous Cell Carcinoma.Cancer medicine · 2024Article
- Disturbed glycolipid metabolism activates CXCL13-CXCR5 axis in senescent TSCs to promote heterotopic ossification.Cellular and molecular life sciences : CMLS · 2024Article
- Mesenteric Lymphatic B Cells Migrate to the Intestine and Aggravate DSS-Induced Colitis via the CXCR5-CXCL13 Axis.Biology · 2024Article
- INVITED COMMENTARY on Andersen S, et al. Developmental Windows of Environmental Vulnerability for Inflammatory Bowel Disease.Journal of pediatrics. Clinical practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CXCL13 is a chemokine that is widely involved in the pathogenesis of autoimmune diseases, tumors and inflammatory diseases. In this study, we investigate the role of CXCL13 in the pathogenesis of inflammatory bowel disease using both clinical specimens and animal models. We found that the serum CXCL13 concentration in IBD patients was significantly higher than that in healthy controls, and correlated with that of CRP, neutrophils counts and hemoglobin. The increase of CXCL13 in IBD patients might be related to the significant decrease of circulating CD4+CXCR5+ T cells, the increase of CD19+CD5+ B cells and the enhancement of humoral immunity. In mice colitis model, we also found elevated levels of CXCL13 in colon tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.